Tactile Systems Technology, Inc. (TCMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$22.02+1.33%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Tactile Systems aims for $360M to $368M revenue in 2026. Adjusted EBITDA target is $49M to $51M. The company has beaten earnings recently and started a $25M share buyback. Revenue growth and margin improvement could restore profitability.
The company had negative operating income and cash flow in Q1 2026. Meeting aggressive revenue and EBITDA targets may be challenging. If cash flow does not improve, financial health could worsen.
The price is about 13% below our fair value near $36. Analysts expect about 10% revenue growth. Our view aligns with moderate growth but sees risks in margin and cash flow recovery.
Breaks if: Adjusted EBITDA falls below $38M in FY26
Target full year 2026 adjusted EBITDA in the range of $49 million to $51 million, improving profitability and operating leverage.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a stable growth investment with a focus on consistent revenue and profitability. The current thesis state is intact, supported by recent strong financial performance and management's clear priorities.
The market appears to have a neutral valuation for TCMD, with expectations slightly below what peers anticipate. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Management is on track to achieve its revenue and adjusted EBITDA targets for 2026, reflecting a strong operational execution. However, there is a near-term risk of missing guidance, which could impact investor sentiment.
The long-term thesis hinges on maintaining revenue growth and profitability while navigating potential sector challenges. Key factors include guidance updates and performance of major healthcare peers, which could influence market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA increased from $44.8 million in 2025 to an expected $49 million to $51 million in 2026. Quarterly adjusted EBITDA rose from $7.7 million in 2025-Q2 to $11.4 million in 2026-Q2. The trajectory shows delivering improved profitability consistent with management's target.
“The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million.”
“The Company continues to expect full year 2026 adjusted EBITDA in the range of $49 million to $51 million.”
“The Company also expects full year 2026 adjusted EBITDA in the range of $49 million to $51 million.”
Breaks if: Cash from operations remains negative for multiple quarters in FY26
Breaks if: Annual revenue falls below $317M in FY26
Continue to grow total revenue to a range of $360 million to $368 million in 2026, representing approximately 9% to 12% year-over-year growth.
In the next 1 to 3 years, TCMD's performance will depend on its ability to meet management targets and the broader healthcare sector's momentum. Not investment advice.